

**IN THE CLAIMS:**

Please cancel claims 2, 5, 7, 10 to 14, 19, 22 to 25, 41 to 43 and 48 without prejudice.

Please amend the claims and add new claims 114 to 134 as follows:

1.-110. (Canceled)

111. (Currently Amended) A purified antibody or functional fragment thereof, wherein said antibody or said functional fragment specifically binds a polypeptide having an approximate molecular weight of 35 or 65 55 or 115 kDa using sodium dodecyl sulfate polyacrylamide gel electrophoresis, and wherein said polypeptide is a ~~polypeptide expressed by ASPC-1 (ATCC Accession No. CRL-1682) and BXPC-3 (ATCC Accession No. CRL-1687) cells and~~ antibody or said functional fragment comprises a sequence at least 80% identical to the sequence of SEQ ID NO:5 or comprises a sequence at least 80% identical to the sequence of SEQ ID NO:7 ~~polypeptide is not expressed by non-neoplastic cells of the same tissue type.~~

112. (Currently Amended) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence ~~that is substantially at least 85%~~ identical to the sequence of SEQ ID NO:1 SEQ ID NO:5 or comprises a sequence at least 85% identical to the sequence of SEQ ID NO:7.

113. (Currently Amended) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence ~~that is substantially at least 90%~~ identical to the sequence of SEQ ID NO:1 SEQ ID NO:5 or comprises a sequence at least 90% identical to the sequence of SEQ ID NO:7.

114. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence at least 95% identical to the sequence of SEQ ID NO:5 or comprises a sequence at least 95% identical to the sequence of SEQ ID NO:7.

115. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof is at least 98% identical to the full length of sequence SEQ ID NO:5 or SEQ ID NO:7.

116. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence at least 80% identical to 90 contiguous amino acids of SEQ ID NO:5 or comprises a sequence at least 80% identical to 90 contiguous amino acids of SEQ ID NO:7.

117. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence at least 85% identical to 90 contiguous amino acids of SEQ ID NO:5 or comprises a sequence at least 85% identical to 90 contiguous amino acids of SEQ ID NO:7.

118. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence at least 90% identical to 90 contiguous amino acids of SEQ ID NO:5 or comprises a sequence at least 90% identical to 90 contiguous amino acids of SEQ ID NO:7.

119. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises a sequence at least 95% identical to 90 contiguous amino acids of SEQ ID NO:5 or comprises a sequence at least 95% identical to 90 contiguous amino acids of SEQ ID NO:7.

120. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment comprises SEQ ID NO:5 and SEQ ID NO:7 with a conservative amino acid substitution in either SEQ ID NO:5 or SEQ ID NO:7.

121. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof includes amino acids 26-34, 52-58 or 97-103 of SEQ ID NO:5, or includes amino acids 11-18, 36-43, or 82-100 of SEQ ID NO:7.

122. (New) The purified antibody or functional fragment thereof of claim 111, wherein said functional fragment comprises a fragment that includes amino acids 26-34, 52-58 and 97-103 of SEQ ID NO:5, or that includes amino acids 11-18, 36-43, and 82-100 of SEQ ID NO:7.

123. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof comprises the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:7.

124. (New) The purified antibody or functional fragment thereof of claim 111, wherein said functional fragment is selected from the group consisting of V<sub>L</sub>, V<sub>H</sub>, F<sub>v</sub>, F<sub>c</sub>, Fab, Fab', and F(ab')<sub>2</sub>.

125. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or said functional fragment is linked or conjugated to a detectable agent.

126. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof specifically binds to a stomach adenocarcinoma, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus, adenocarcinoma of the pancreas, urothelial carcinoma of the urinary bladder, renal cell carcinoma of the kidney, adenocarcinoma of the prostate, ductal carcinoma of the breast, lobular carcinoma of the breast, adenocarcinoma of the ovary, adenocarcinoma of the endometrium, or adenocarcinoma of the uterus cell.

127. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof specifically binds to and inhibits proliferation of a stomach adenocarcinoma, colorectal adenocarcinoma, squamous cell lung carcinoma, lung adenocarcinoma, squamous cell carcinoma of the esophagus, adenocarcinoma of the pancreas, urothelial carcinoma of the urinary bladder, renal cell carcinoma of the kidney, adenocarcinoma of the prostate, ductal carcinoma of the breast,

lobular carcinoma of the breast, adenocarcinoma of the ovary, adenocarcinoma of the endometrium, or adenocarcinoma of the uterus cell.

128. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof inhibits proliferation of BXPC-3 (ATCC Accession No. CRL-1687) cells.

129. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof induces apoptosis of BXPC-3 (ATCC Accession No. CRL-1687) cells.

130. (New) The purified antibody or functional fragment thereof of claim 111, wherein said antibody or functional fragment thereof specifically binds to CACO-2 cell line (ATCC Accession No. HBT-37), COLO-320 cell line (DSMZ Accession No. ACC 144), or COLO-206F cell line (DSMZ Accession No. ACC 21).

131. (New) A purified antibody or functional fragment thereof, comprising the amino acid sequence of SEQ ID NO:5.

132. (New) A purified antibody or functional fragment thereof, comprising the amino acid sequence of SEQ ID NO:7.

133. (New) A purified antibody or functional fragment thereof, comprising the amino acid sequence of SEQ ID NO:5 and SEQ ID NO:7.

134. (New) An antibody produced by the PM-2 cell line having DSMZ Accession No. DSM ACC2600.